

1/22




Figure 1

2/22





Figure 2

3/22





Figure 3

4/22





Figure 4

5/22





Figure 5

6/22




Figure 6

7/22




Figure 7A

Dose-Response






Figure 7C

Figure 7B



8/22



9/22





Figure 9B

Figure 9A

10/22





Figure 10


11/22

49 RLM

| Phase I |                  |           |         |      |                           |
|---------|------------------|-----------|---------|------|---------------------------|
| Time    | analyte(x<br>Eq) | IS (x Eq) | Anal/IS | Time | Anal/IS<br>%<br>remaining |
| 0       | 362568.9         | 122506.3  | 2.96    | 0    | 2.960 100%                |
| 5       | 94160.69         | 96904.59  | 0.97    | 5    | 0.972 33%                 |
| 10      | 102579.3         | 86205     | 1.19    | 10   | 1.190 40%                 |
| 30      | 15490.61         | 20383.62  | 0.76    | 30   | 0.760 26%                 |
| 60      | 1669.361         | 2080.87   | 0.80    | 60   | 0.802 27%                 |

49 RLM

| Phase I & II |                  |           |          |      |                           |
|--------------|------------------|-----------|----------|------|---------------------------|
| Time         | analyte(x<br>Eq) | IS (x Eq) | Anal/IS  | Time | Anal/IS<br>%<br>remaining |
| 0            | 321910           | 173842.4  | 1.851735 | 0    | 1.852 100%                |
| 5            | 128793.7         | 96268.7   | 1.337856 | 5    | 1.338 72%                 |
| 10           | 90651.26         | 76381.49  | 1.186822 | 10   | 1.187 64%                 |
| 30           | 26980            | 25681.36  | 1.050567 | 30   | 1.051 57%                 |
| 60           | 8411.491         | 16090     | 0.522778 | 60   | 0.523 28%                 |



|                 | 49 RLM Phase I | 49 RLM Phase II |
|-----------------|----------------|-----------------|
| Clearance       | 0.1106         | 0.01906         |
| Half Life (min) | 6.266          | 36.36           |

Figure 11

12/22






Figure 12



|                 | phase I MLM | phase II MLM |
|-----------------|-------------|--------------|
| Clearance       | 0.007395    | 0.01261      |
| Half Life (min) | 93.73       | 54.96        |

Figure 13

14/22




Figure 14




Figure 15

16/22




Figure 16




Figure 17B

Figure 17A

18/22




Figure 18

19/22




Figure 19

20/22




Figure 20

21/22




Figure 21

22/22




Figure 22